101. Pharmacogenomics Reporter | DxPGx | GenomeWeb Journal articles and exclusive reports on human genetic variations and their effects on response to drugs. This is a GenomeWeb online publication. http://www.pgxreporter.com

Search Home News GenomeWeb Daily News BioArray News ... Log in or Register Sunday, October 31, 2010 Arrays Bioregionnews Biotechtransferweek Cbanews ... Pharmacogenomics Reporter Type size: RSS Feed FDA Issues Draft Guidelines on Qualifying Biomarkers to Speed Rx Development The draft document, titled "Qualification Process for Drug Development Tools," lays out the process by which industry can receive FDA's go-ahead for biomarkers, including pharmacogenomic markers, for use in a specific context. After getting these biomarkers "qualified" by the FDA, industry can use these markers in a similar context in multiple drug trials, drug classes, or clinical disorders, without having to repeatedly seek the agency's approval. October 29, 2010 When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In Although some industry observers suggest that Boehringer Ingelheim's newly FDA-approved anticoagulant spells the end for PGx-guided warfarin dosing, some still see opportunities where warfarin administration, made more accurate with genetic testing, may be a better option for patients. October 27, 2010

102. Welcome To EntroGen, Inc Offers pharmacogenomic tests to clinical diagnostic laboratories and research institutions. http://www.entrogen.com

103. The Pharmacogenomics Journal Dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications. http://www.nature.com/tpj/

Jump to main content Jump to navigation nature.com homepage ... Login Search This journal All of nature.com Advanced search Welcome to The Pharmacogenomics Journal The Pharmacogenomics Journal is dedicated to the rapid publication of original research on basic pharmacogenomics research and its clinical applications. Publishing six times a year, the journal aims to provide the highest caliber of coverage concerning the effects of genetic variablity on drug toxicity and efficacy, the characterization of polymorphisms relevant to drug action, and the identification of novel genomic targets for drug development. Looking for more information on pharmacogenomics? Read about its scope, limitations and applications in this article , featuring The Pharmacogenomics Journal 's own Julio Licinio. *** Announcing Open Access publication option *** The Pharmacogenomics Journal now offers authors the option to publish their articles with immediate open access upon publication. Open access articles will also be deposited on PubMed Central at the time of publication and will be freely available immediately. Find out more from the press release or our FAQs page First International Conference on Translational Medicine November 1 st th 2010, Canberra, Australia

104. OncoGenetics.Org Provides readers with an in-depth coverage of the latest developments in oncology, pharmacogenomics, and genetics. http://www.oncogenetics.org

Home About Us Contact basic research News, reviews and commentaries about the latest developments in cancer research. clinical research Information about the most recent advances in clinical oncology and research. Overview of known genetic and epigenetic alterations that lead to cancer. cancer diagnostics News about the latest technologies being used in diagnosis and treatment. resources List of organizations, journals and websites relevant to cancer research and genetics. DNAVISION ORDERS SECOND ILLUMINA HISeq2000™ FOR COMMERCIAL USE Submitted by Staff on Fri, 08/27/2010 Brussels (Belgium) 27th August 2010 – DNAVision, Europe’s leading genetic analysis service providers, is pleased to announce the acquisition beginning of August of an additional Illumina HiSeq 2000 sequencing platform. The new system will be ready for service to customer early October, just a few months after the first HiSeq system has successfully entered into operation. Due to the high cost-effectiveness and sequencing output, DNAVision uses the HiSeq 2000 systems mainly for human genome sequencing. About DNAVision Read more DNAVISION ORDERS EUROPE’S FIRST HIScanSQ™ FOR COMMERCIAL USE Submitted by Staff on Mon, 05/17/2010

105. American Journal Of Therapeutics Access to full-text content, online-only content, features and services, author submission materials and title-specific information. An LWWonline partner. http://www.americantherapeutics.com

106. Drug Discovery & Development Articles covering genomics, bioinformics, cellular biology, transgenics and stem cell research as it applies to the medical and pharmaceutical industries. http://www.dddmag.com/Default.aspx

107. Home : Nature Reviews Drug Discovery A monthly journal aimed at dealing with drug discovery and development. http://www.nature.com/nrd/

Jump to main content Jump to navigation nature.com homepage ... Login Search This journal All of Nature.com Advanced search Nature Reviews Drug Discovery Volume 9, No 11 November 2010 Featured Article The importance of new companies for drug discovery: origins of a decade of new drugs Robert Kneller Main pages for finding content: Current issue Advance online publication Archive Noticeboard 2009 ISI Impact Factor Source of Impact Factor data) Next issue date: 1 December 2010 Current issue News Modifying protein misfolding Dan Jones Two recent deals highlight growing interest in therapeutically targeting protein misfolding to treat both rare and common diseases. Advance online publication News First oral warfarin alternative approved in the US Bethan Hughes For more than 50 years, warfarin has been the standard of care for long-term anticoagulation therapy in the United States, but now the FDA has approved the first oral anticoagulant that could replace it. Current issue Case Histories Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis Current Issue Research Highlights Analgesics: Pain control at the periphery Inflammatory disorders: Constraining the complement cascade Antimalarial drugs: Speeding to a new lead Current Issue Perspective Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements This article discusses the lessons learned from the evaluation of combinations of molecularly targeted anticancer agents by the US National Cancer Institute (NCI), and highlights several new approaches that the NCI has initiated to improve the effectiveness of such combinations.

108. An Error Occurred Setting Your User Cookie A quarterly publication, available on subscription, covering all aspects of drug evaluation. http://www.pjbpubs.com/cms.asp?pageid=979

Page 6     101-108 of 108    Back | 1  | 2  | 3  | 4  | 5  | 6